The latest update is out from Rhythm Pharmaceuticals ( (RYTM) ).
On March 14, 2025, Rhythm Pharmaceuticals announced the termination of its licensing and share purchase agreements with RareStone Group Ltd., reacquiring the rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau. This strategic move allows Rhythm to own the global franchise for setmelanotide, aligning with its strategy to develop and commercialize treatments for rare neuroendocrine diseases worldwide. The termination agreement includes a repayment of $6.3 million to RareStone and the return of acquired shares without additional consideration, releasing all parties from any claims related to the previous agreements.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company based in Boston, MA, focused on transforming the lives of patients with rare neuroendocrine diseases. Its lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved for treating hyperphagia and severe obesity due to specific genetic conditions. The company is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists.
YTD Price Performance: -8.09%
Average Trading Volume: 504,327
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.31B
For a thorough assessment of RYTM stock, go to TipRanks’ Stock Analysis page.